Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces First Patient Completes Hemopurifier® Clinical Study Protocol
SAN DIEGO - February 26, 2015 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD),
the pioneer in developing targeted therapeutic devices to address infectious
diseases and cancer, today announced that the first patient enrolled in the
Company's FDA approved feasibility study has completed their full Hemopurifier®
treatment protocol without any device-related adverse events. The study
protocol, which is being administered at DaVita Med Center Dialysis in Houston,
is enrolling ten chronic dialysis patients infected with Hepatitis C virus
(HCV) to receive a six treatment protocol of Hemopurifier therapy. The Aethlon
Hemopurifier is a first-in-class bio-filtration device that provides the
broad-spectrum elimination of infectious viruses from the circulatory system of
infected individuals.
The
feasibility study will contribute safety data to advance the Hemopurifier as a
candidate therapy to address chronic conditions such as HIV and HCV, as well as
acute bioterror and pandemic threats that are not addressed with proven drug or
vaccine therapies. A detailed description of the study, including treatment
protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov
"With
our feasibility study now under way, we will initiate our previously
communicated plan to file Humanitarian Use Device (HUD) submissions that
provide a potential FDA market clearance pathway to treat viral indications
that affect fewer than 4,000 individuals in the U.S. each year," stated
Jim Joyce, Chairman and CEO of Aethlon Medical.
To
date, Hemopurifier therapy has been administered outside the United States in
the treatment of Ebola, HIV and HCV-infected individuals. Previously, in vitro
studies of bioterror and pandemic threats have verified Hemopurifier capture of
Ebola hemorrhagic virus, dengue hemorrhagic virus, lassa hemorrhagic virus,
H5N1 avian influenza (bird flu), the reconstructed 1918 influenza virus
(r1918), 2009 H1N1 influenza virus (swine flu), West Nile virus, and monkeypox,
which serves as a model for human smallpox infection. These studies were
conducted with leading government and non-government research organizations,
including The U.S. Army Medical Research Institute of Infectious Diseases
(USAMRIID), The Centers for Disease Control and Prevention (CDC), The National
Institute of Virology (NIV), The Battelle Biomedical Research Center (BBRC) and
The Southwest Foundation for Biomedical Research (SFBR).
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease, cancer and neurodegenerative disorders. The company's lead
product is the Aethlon Hemopurifier®, a first-in-class device that selectively
targets the rapid elimination of circulating viruses and tumor-secreted
exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority
owned subsidiary that is advancing exosome-based products to diagnose and
monitor cancer, infectious disease and neurological disorders. Additional
information can be found online at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when needed,
the Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news
submissions, content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each release if
required but otherwise the news was not compensated for and is published for
the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
This comment has been removed by the author.
ReplyDelete